Table 1.

Demographic and clinical features of the evaluated patients.

Patients	Three hundred forty seven patients	Thirteen patients with VTE
Gender (female/male)	87.6%/12.4%	84.6%/15.4%
ACR/EULAR 2010 classificative criteria	100.0%	100%
Age, mean ± SD, yr	66.1 ± 11.3	59.3 ± 10.4
Disease duration at the first observation, median (range), yr	5 (28)	6 (7)
RF and/or ACPA	66.1%	61.5%
Extra-articular disease	11.5%	7.6%
Smoking habit	47.8%	69.2%
GCs low dose	73.9%	76.9%
GCs high dose	26.1%	23.1%
MTX	69.7%	69.2%
LEF	17.6%	23.1%
SSZ	9.5%	0%
HCQ	18.1%	7.7%
Biologic DMARDs	47.1%	69.2%
TNFi	35.3%	35.9%
Non-TNFi	11.8%	33.3%
Targeted synthetic DMARDs	2.8%	0%

ACPA = anti-citrullinated protein antibody, DMARD = disease-modifying anti-rheumatic drug, GCs = glucocorticoids, HCQ = hydroxychloroquine, LEF = leflunomide, MTX = methotrexate, RF = rheumatoid factor, SSZ = sulfasalazine, TNFis = tumor necrosis factor.